How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Allogeneic Stem Cell Therapy Market
- By Product Type: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, Multipotent Adult Progenitor Cells
- By Application: Oncology, Autoimmune Diseases, Cardiovascular Diseases, Orthopedic Disorders, Neurological Disorders
- By Source: Umbilical Cord Blood, Bone Marrow, Peripheral Blood, Placental Tissue
- By End User: Hospitals, Specialty Clinics, Research Institutes, Contract Research Organizations
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hematopoietic Stem Cells leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Allogeneic Stem Cell Therapy Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 4
Application 5
Source 4
End User 4
Companies profiled
Fate Therapeutics Inc.
Mesoblast Limited
Athersys Inc.
Pluristem Therapeutics Inc.
Celyad Oncology SA
TiGenix NV (now part of Takeda Pharmaceutical Company)
Vericel Corporation
Nkarta Therapeutics Inc.
AlloVir Inc.
Kiadis Pharma (a Sanofi company)
Bellicum Pharmaceuticals Inc.
Cellular Biomedicine Group Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fate Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Mesoblast Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Athersys Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pluristem Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Celyad Oncology SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →TiGenix NV (now part of Takeda Pharmaceutical Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Vericel Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nkarta Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AlloVir Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Kiadis Pharma (a Sanofi company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Bellicum Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cellular Biomedicine Group Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Caladrius Biosciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Atara Biotherapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Gamida Cell Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,755M by 2033 · 9.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hematopoietic Stem Cells50.8
- Mesenchymal Stem Cells18.0
- Induced Pluripotent Stem Cells12.4
- Multipotent Adult Progenitor Cells18.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$920.5M → $2,095M · 10.8%
Europe$641.6M → $1,323M · 9.5%
Asia Pacific$585.8M → $1,298M · 10.5%
Latin America$362.6M → $758.9M · 9.7%
Middle East and Africa$278.9M → $538.7M · 8.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.432026
9.432027
9.452028
9.462029
9.482030
9.502031
9.492032
9.512033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fate Therapeutics Inc.20.2
- Mesoblast Limited15.7
- Athersys Inc.10.4
- Pluristem Therapeutics Inc.12.9
- Celyad Oncology SA6.0
- TiGenix NV (now part of Takeda Pharmaceutical Company)6.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type30.7%
Application13.5%
Source24.2%
End User31.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.8
- Europe22.0
- Asia Pacific21.6
- Latin America12.6
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | 86 | 89 | 78 | 96 | 94 | 96 | 90 |
| Mesoblast Limited | 92 | 75 | 79 | 85 | 92 | 89 | 85 |
| Athersys Inc. | 70 | 69 | 70 | 80 | 71 | 86 | 74 |
| Pluristem Therapeutics Inc. | 58 | 74 | 80 | 64 | 66 | 81 | 71 |
| Celyad Oncology SA | 58 | 75 | 59 | 71 | 59 | 52 | 62 |
| TiGenix NV (now part of Takeda Pharmaceutical Company) | 51 | 52 | 63 | 49 | 52 | 54 | 54 |
| Vericel Corporation | 62 | 47 | 64 | 49 | 64 | 64 | 58 |
| Nkarta Therapeutics Inc. | 58 | 56 | 54 | 42 | 60 | 38 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fate Therapeutics Inc.
- Mesoblast Limited
- Athersys Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fate Therapeutics Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Mesoblast Limited | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Athersys Inc. | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Pluristem Therapeutics Inc. | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Celyad Oncology SA | ◐ | ◐ | − | ◐ | ◐ | − |
| TiGenix NV (now part of Takeda Pharmaceutical Company) | − | − | ◐ | − | − | ◐ |
| Vericel Corporation | ◐ | − | ◐ | ◐ | − | ◐ |
| Nkarta Therapeutics Inc. | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fate Therapeutics Inc.90
2Mesoblast Limited85
3Athersys Inc.74
4Pluristem Therapeutics Inc.71
5Celyad Oncology SA62
6Vericel Corporation58
7TiGenix NV (now part of Takeda Pharmaceutical Company)54
8Nkarta Therapeutics Inc.51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fate Therapeutics Inc.Mesoblast Limited
Challenger2
Strong scale, closing on the leaders.
Athersys Inc.Pluristem Therapeutics Inc.
Contender2
Focused players with pockets of strength.
Celyad Oncology SAVericel Corporation
Niche2
Specialists in a single segment or region.
TiGenix NV (now part of Takeda Pharmaceutical Company)Nkarta Therapeutics Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Allogeneic Stem Cell Therapy Market — a $373M beachhead inside a $7.54B market.
Beachhead (SOM)$373Mobtainable near-term
Serviceable (SAM)$2.58Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Hematopoietic Stem Cells
Best fit — highest urgency & budget in Product Type.
Economic buyer79 fit
Mesenchymal Stem Cells
Strong fit — clear ROI and a fast path to value.
End user68 fit
Induced Pluripotent Stem Cells
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Source
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel26%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Allogeneic Stem Cell Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation12%
Closed-won6%
$16.8KCAC
$87KLTV
5.2:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Allogeneic Stem Cell Therapy Market is a durable-growth opportunity — $7.50B by 2033, compounding at 6.8%.
TAM · 2025$4.42Btoday
TAM · 2033$7.50Bforecast
CAGR6.8%2027–2033
Cumulative$52.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.50BTotal addressable market
SAM$3.03BServiceable available market
SOM$506MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.8% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.50BLarge & growingTAM by 2033 at 6.8% CAGR
$3.03BServiceable nowreachable with today’s model
$506MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.85BBear4.4% CAGR
$7.50BBase6.8% CAGR
$9.60BBull9.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Allogeneic Stem Cell Therapy Market — a $5.53B market by 2033. Plan: grow share from 7.3% to 12.4%.
Market size · 2033$5.53Btotal addressable
Market CAGR10.3%2027–2033
Target share12.4%from 7.3% today
Revenue ambition$686Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 12.4% | On track |
| Revenue | $442M | $686M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 32.2% | 39.5% | On track |
| Customer retention | 89.7% | 95.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $77M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Allogeneic Stem Cell Therapy Market conversation — a $4.20B market you can size, segment and defend in minutes.
Market size · 2033$4.20Btotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,144+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 4 mopayback period
$41K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Fate Therapeutics Inc.Mesoblast LimitedAthersys Inc.Pluristem Therapeutics Inc.Celyad Oncology SATiGenix NV (now part of Takeda Pharmaceutical Company)Vericel CorporationNkarta Therapeutics Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Allogeneic Stem Cell Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Allogeneic Stem Cell Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Desmopressin Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportAllogeneic Stem Cells Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportDesmopressin Acetate Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportAllogeneic Human Chondrocyte Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportDaunorubicin Hydrochloride (CAS 23541-50-6) Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAllogeneic Bone Implant Materials Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAllogeneic Bone Graft Substitutes Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportKidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAllogeneic Bone Graft Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCinacalcet Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCilastatin Sodium Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCiclesonide Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.